Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen sent this email to their subscribers on October 30, 2024.

October 29, 2024 6:01 PM EDT

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

View this release

Text-only version of this email

Biogen Inc. October 29, 2024 6:01 PM EDT Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases View this release You are subscribed to Biogen Inc. Investor Relations' email alerts. Visit the website | View releases | Biogen Inc. 225 Binney Street , Cambridge, Massachusetts 02142, United States Service provided by Notified

Show all

The Latest Emails Sent By Biogen

New Form 8-K for Biogen Inc.

New Form 8-K for Biogen Inc.

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Biogen Appoints Adam Feire as Head of Business Development and External Innovation

Biogen Appoints Adam Feire as Head of Business Development and External Innovation

New Form 3 for Biogen Inc.

New Form 3 for Biogen Inc.

New Form 4 for Biogen Inc.

New Form 4 for Biogen Inc.

New Form 4 for Biogen Inc.

New Form 4 for Biogen Inc.

More Emails, Deals & Coupons From Biogen

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

Biogen Reports Progress on Corporate Responsibility Priorities

Biogen Reports Progress on Corporate Responsibility Priorities

New Form 3 for Biogen Inc.

New Form 3 for Biogen Inc.

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease

CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease

New Form SC 13G/A for Biogen Inc.

New Form SC 13G/A for Biogen Inc.

New Form 144 for Biogen Inc.

New Form 144 for Biogen Inc.

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor

New Form 144 for Biogen Inc.

New Form 144 for Biogen Inc.

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

New Form 8-K for Biogen Inc.

New Form 8-K for Biogen Inc.

New Form 8-K for Biogen Inc.

New Form 8-K for Biogen Inc.

Email Offers, Discounts & Promos From Our Top Stores